Anti-topoisomerase-I and clinical findings in systemic sclerosis (scleroderma).
The relationship between anti-topoisomerase-I antibodies and clinical findings was studied in 191 patients with definite systemic sclerosis. This was done by performing ELISA to detect antibodies to recombinant topoisomerase-I. Antibodies to topoisomerase-I were found in 72 patients (37%) with systemic sclerosis, which is a higher percentage than reported in most previous reports on a large unselected population. In 43 patients the presence of antibodies to recombinant topoisomerase-I was confirmed using both the immunodiffusion method and ELISA, with similar results. When classified into diffuse versus limited disease, a significant difference in antibody prevalence was demonstrated (P < 0.005), thus indicating that anti-topoisomerase-I antibody detection with ELISA may assist in early identification of systemic sclerosis subtypes.
Shoenfeld
Y
Y
Department of Medicine B, Chaim Sheba Medical Center, Tel-Hashomer, Israel.
Grunebaum
E
E
Laufer
M
M
Zurgil
N
N
Bakimer
R
R
Lunderschmidt
A
A
Valentini
G
G
Tirri
G
G
Blank
M
M
D001323:Autoantibodies / Q000097:blood*; D004264:DNA Topoisomerases, Type I / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D006801:Humans; D005779:Immunodiffusion; D015994:Incidence; D015995:Prevalence; D015203:Reproducibility of Results; D012595:Scleroderma, Systemic / Q000145:classification / Q000201:enzymology / Q000276:immunology*; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index
D001323:Autoantibodies; D004264:DNA Topoisomerases, Type I